Search

Search Results

• INFLUENZA AND PNEUMOCOCCAL VACCINATION IN HEMATOLOGICAL MALIGNANCIES: A SYSTEMATIC REVIEW OF EFFICACY, EFFECTIVENESS AND SAFETY

  Giuseppe La Torre

  e2016044

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.044

  4714

  PDF: 1487

  HTML: 3145

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2149

  PDF: 1707

  HTML: 380

• MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

  Ibrahim C. Haznedaroglu

  e2014009

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.009

  4000

  PDF: 1520

  HTML: 9191

  Untitled: 281

  Untitled: 188

  Untitled: 173

  Untitled: 167

  Untitled: 189

  Untitled: 344

• TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment

  Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo

  e2022040

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.040

  2113

  PDF: 1533

  HTML: 495

• CYTOKINE RESPONSE ASSOCIATED WITH HEPATITIS C VIRUS CLEARANCE IN HIV COINFECTED PATIENTS INITIATING PEG INTERFERON-? BASED THERAPY.

  Truong Tam Nguyen, Reihani Niloofar, Pierre-Alain Rubbo, Kuster Nils, Karine Bollore, Jacques Ducos, Georges-Philippe Pageaux, Jacques Reynes, Philippe Van de Perre, Edouard Tuaillon

  e2016003

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.003

  3146

  PDF: 917

  HTML: 2051

  Untitled: 179

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

  Michele Bibas, Shayna Sarosiek , Jorge Castillo

  e2025015

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.015

  2553

  PDF: 2019

  HTML: 219

• OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY

  Mohamed Amine BEKADJA

  e2017062

  2017-10-25

  https://doi.org/10.4084/mjhid.2017.062

  2863

  PDF: 735

  HTML: 912

• PROGNOSTIC SIGNIFICANCE OF TRANSCRIPT-TYPE BCR/ABL1 IN CHRONIC MYELOID LEUKEMIA

  matteo molica, elisabetta abruzzese, massimo breccia

  e2020062

  2020-09-12

  https://doi.org/10.4084/mjhid.2020.062

  3708

  PDF: 1601

  HTML: 646

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

  Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi

  e2018004

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.004

  7642

  PDF: 2431

  HTML: 1739

  Table 1.: 211

  Table 2.: 219

  Table 3.: 205

  Table 4.: 204

• Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA

  Bhavya S Doshi, Valder R Arruda, Valder R Arruda

  e2020069

  2020-09-08

  https://doi.org/10.4084/mjhid.2020.069

  2073

  PDF: 1898

  HTML: 350

• CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,

  Ugo Testa, Giuseppe Leone, Elvira Pelosi, Dr. Germana Castelli, Prof. Hohaus

  e2023066

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.066

  3723

  PDF: 1457

  HTML: 186

• RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC

  Rawanda Shamoon, Ahmed K. Yassin, Sara L. Alnuaimi

  e2024019

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.019

  1060

  PDF: 1166

  HTML: 80

• THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

  Elvira Pelosi, Dr. Germana Castelli, Ugo Testa

  e2022080

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.080

  1508

  PDF: 1158

  HTML: 284

• TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin

  Cristina Papayannidis, Vincenzo Federico, Luana Fianchi, Patrizia Pregno, Novella Pugliese, Alessandra Romano, Federica Irene Grifoni

  e2022073

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.073

  1256

  PDF: 1006

  HTML: 223

• LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE

  Patrizia Tosi

  e2013037

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.037

  1295

  PDF: 898

  HTML: 1280

  fig 1A: 174

  figure1B: 150

• LIGHT CHAIN AMYLOIDOSIS

  Paolo Milani, Giampaolo Merlini, Giovanni Palladini

  e2018022

  2018-03-01

  https://doi.org/10.4084/mjhid.2018.022

  5749

  PDF: 2328

  HTML: 1337

• IMMUNOLOGY OF TUBERCULOSIS

  Federica Bozzano, Francesco Marras, Andrea De Maria

  e2014027

  2014-04-07

  https://doi.org/10.4084/mjhid.2014.027

  5346

  PDF: 2017

  HTML: 7333

  Untitled: 195

• Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments

  NICOLA SGHERZA, Anna Mestice, Angela Maria Vittoria Larocca, Pellegrino Musto

  e2024022

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.022

  753

  PDF: 1149

  HTML: 86

• CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment

  Ugo Testa, Elvira Pelosi, Dr. Germana Castelli

  e2024077

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.077

  1743

  PDF: 848

  HTML: 151

• CLINICAL SIGNS AND TREATMENT OF NEW-ONSET BONE MARROW FAILURE ASSOCIATED SARS-COV-2 INFECTION IN CHILDREN : A SINGLE INSTITUTION PROSPECTIVE COHORT STUD

  Mervat A M youssef, Ebtisam Shawky hmed, Dalia Tarik Kamal, khalid Elsayh,, Mai A Abdelfatta, Hyam Hassan Mahran Mahran, Mostafa M Embaby

  e2024034

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.034

  1213

  PDF: 1301

  HTML: 123

• IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?

  Giuseppe Gritti, Chiara Pavoni, Alessandro Rambaldi

  e2017010

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.010

  3388

  PDF: 1289

  HTML: 2223

  Fi.1 Gritti.Rambaldi: 206

• MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA Guest Editor: Giancarlo Costaman

  Davide Matino, Paul Tieu, Dr., Antony Chan

  e2020001

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.001

  3285

  PDF: 1615

  HTML: 443

• “IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”

  Sara Martinelli, Antonio Cuneo, Gian Matteo Rigolin

  e2016047

  2016-10-15

  https://doi.org/10.4084/mjhid.2016.047

  4009

  PDF: 1056

  HTML: 3599

  Untitled: 177

  Cneo. Fig.1: 114

  Untitled: 105

  Untitled: 128

  Untitled: 134

• CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL

  Ugo Testa, Prof. Sica, Dr. Pelosi, Dr. Germana Castelli, Prof. Leone

  e2024010

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.010

  4249

  PDF: 3510

  HTML: 217

• TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

  Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso

  e2017045

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.045

  4361

  PDF: 1767

  HTML: 1111

• Morphologic leukemia-free state after venetoclax-based therapy in acute myeloid leukemia is associated with high relapse despite preserved short-term survival

  Kenta Motegi

  e2026048

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.048

  260

  PDF: 286

  HTML: 19

• PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?

  Kalliopi Zachou, Pinelopi Arvaniti, Nikolaos K. Gatselis, Kalliopi Azariadis, Georgia Papadamou, Eirini Rigopoulou, George N. Dalekos

  e2017003

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.003

  2946

  PDF: 983

  HTML: 2065

  Cover letter: 180

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3770

  PDF: 1069

  HTML: 2055

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1779

  PDF: 1684

  HTML: 878

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2132

  PDF: 1156

  HTML: 2009

• USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS

  Paola Mancino, Katia Falasca, Claudio Ucciferri, Eligio Pizzigallo, Jacopo Vecchiet

  e2010003

  2010-03-26

  https://doi.org/10.4084/mjhid.2010.003

  1111

  PDF: 523

  HTML: 827

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  1981

  PDF: 758

  HTML: 702

• DIAMOND BLACKFAN ANEMIA: A TERTIARY CARE CENTRE EXPERIENCE

  avinash kumar singh, tulika seth, nita radhakrishnan, pravas mishra, manoranjan mahapatra, haraprasad pati

  e2013039

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.039

  1820

  PDF: 858

  HTML: 3594

  Diamond Blackfan Anemia: A Tertiary care centre experience: 258

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2164

  PDF: 743

  HTML: 1633

• BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL

  Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo

  e2024070

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.070

  1652

  PDF: 1100

  HTML: 125

• DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

  Ibrahim C. Haznedaroglu

  e2015014

  2015-12-02

  https://doi.org/10.4084/mjhid.2015.014

  277682

  PDF: 1801

  HTML: 3873

• THALIDOMIDE FOR PATIENTS WITH THALASSEMIA INTERMEDIA: A RETROSPECTIVE MULTICENTER CLINICAL STUDY

  Kun Yang, Yi Wu, Yali Zhou, Tianhong Zhou, Li Wang, Zhili Geng, Xiaolin Yin

  e2020021

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.021

  2202

  PDF: 1239

  HTML: 341

• INFECTIOUS AETIOLOGY OF MARGINAL ZONE LYMPHOMA AND ROLE OF ANTI-INFECTIVE THERAPY

  Salvatore Perrone, Gianna Maria D'Elia, Alessandro Pulsoni

  e2016006

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.006

  4457

  PDF: 1333

  HTML: 2159

• TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Gianantonio Rosti

  e2014005

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.005

  3355

  PDF: 1480

  HTML: 4014

• CLASSICAL HODGKIN LYMPHOMA TODAY

  Francesco D'Alò, Gabriele Schiaffini, Daniele Mazzoni, Eleonora Alma, Flaminia Bellisario, Marcello Viscovo, Elena Maiolo, Silvia Bellesi, Stefan Hohaus

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.055

  130

  PDF: 41

  HTML: 30

• IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

  Tomasz Sacha

  e2014007

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.007

  4794

  PDF: 2848

  HTML: 2296

• SEPSIS-ASSOCIATED DISSEMINATED INTRAVASCULAR COAGULATION AND THROMBOEMBOLIC DISEASE

  Nicola Semeraro, Concetta T. Ammollo, Fabrizio Semeraro, Mario Colucci

  e2010024

  2010-08-06

  https://doi.org/10.4084/mjhid.2010.024

  3355

  PDF: 1773

  HTML: 4551

• THE USE OF MONOCLONAL ANTIBODIES IN THE TREATMENT OF AUTOIMMUNE COMPLICATIONS OF CHRONIC LYMPHOCYTIC LEUKEMIA

  Luca Laurenti

  e2013027

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.027

  2192

  PDF: 1040

  HTML: 2721

• NATION-WIDE SURVEY ON THE USE OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) FOR THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA IN CURRENT CLINICAL PRACTICE IN ITALY

  Francesco Rodeghiero, Dr. Mariasanta Napolitano, Nicola Vianelli, Lisanna Ghiotto, Silvia Cantoni, Giuseppe Carli, Monica Carpenedo, Valentina Carrai, Ugo Consoli, Gaetano Giuffrida, Elisa Lucchini, Elena Rossi, Cristina Santoro

  e2023019

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.019

  2001

  PDF: 1224

  PDF Appendix: 666

  HTML: 439

• Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited

  IOANNIS KOTSIANIDIS

  e2019045

  2019-06-25

  https://doi.org/10.4084/mjhid.2019.045

  1096

  PDF: 848

  HTML: 248

• DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA

  Juan Eduardo Megias-Vericat, David Martínez-Cuadrón, Joaquin Martínez López, Juan Miguel Bergua, Mar Tormo, Josefina Serrano, Ataulfo González, Jaime Pérez de Oteyza, Susana Vives, Belen Vidriales, Pilar Herrera, Juan Antonio Vera, Aurelio López Martínez, Adolfo De la Fuente, María Lourdes Amador, José Ángel Hernández-Rivas, María Ángeles Fernández, Carlos Javier Cerveró, Daniel Morillo, Pilar Hernández Campo, Julián Gorrochategui, Daniel Primo, José Luis Rojas, Margarita Guenova, Joan Ballesteros, Miguel Ángel Sanz, Pau Montesinos

  e2019016

  2019-02-26

  https://doi.org/10.4084/mjhid.2019.016

  1891

  PDF: 1121

  HTML: 261

• APLASTIC ANEMIA AND VIRAL HEPATITIS

  Laura Cudillo

  e2009026

  https://doi.org/10.4084/mjhid.2009.026

  1269

  PDF: 530

  HTML: 23079

• HODGKIN LYMPHOMA IN CHILDREN: A 16-YEAR EXPERIENCE AT THE CHILDREN’S WELFARE TEACHING HOSPITAL OF BAGHDAD, IRAQ

  Anna Maria Testi, Mazin Faisal Al-Jadiry, Maria Luisa Moleti, Stefania Uccini, Amir Fadhil Al-Darraij, Raghad Majid Al-Saeed, Hasanein Habeeb Ghali, Ahmed Hatem Sabhan, Samaher Abdulrazzaq Fadhil, Safaa Abdulelah Al-Badri, Adil Rabeea Alsaadawi, Ameer Dh Hameedi, Manhal Hashim Shanshal, Yasir Saadoon Al-Agele, Fatimah Abdul Ridha Al-Saffar, Nihal Khalid Yaseen, Alfonso Piciocchi, Giovanni Marsili, Salma Abbas Al-Hadad

  e2024053

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.053

  1046

  PDF: 939

  Suppl. Files: 595

  HTML: 88

• Bortezomib maintenance for the treatment of Monoclonal Gammopathy of Renal Significance

  Holly Lee, Peter Duggan, Ernesta Paola Neri, Jason Tay, Victor Jimenez Zepeda

  e2019007

  2019-01-01

  https://doi.org/10.4084/mjhid.2019.007

  2204

  PDF: 1180

  HTML: 339

• BACTERIAL INFECTIONS FOLLOWING SPLENECTOMY FOR MALIGNANT AND NONMALIGNANT HEMATOLOGIC DISEASES

  Giuseppe Leone, Eligio Pizzigallo

  e2015057

  2015-10-12

  https://doi.org/10.4084/mjhid.2015.057

  4894

  PDF: 1980

  HTML: 8407